CADTH Canadian Drug Expert Committee recommendation: Efinaconazole (Jublia -- Bausch Health, Canada Inc.) indication : for the topical treatment of mild to moderate onychomycosis (tinea unguium) of toenails without lunula involvement due to Trichophyton rubrum and Trichophyton mentagrophytes in immunocompetent adult patients
The CADTH Canadian Drug Expert Committee (CDEC) recommends that efinaconazole not be reimbursed for the topical treatment of mild to moderate onychomycosis (tinea unguium) of toenails. Reasons for the Recommendation: 1. Several medications used to treat onychomycosis in Canada are reimbursed by the...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
May 2019, 2019
|
| Edition: | Version 1.0. (final) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that efinaconazole not be reimbursed for the topical treatment of mild to moderate onychomycosis (tinea unguium) of toenails. Reasons for the Recommendation: 1. Several medications used to treat onychomycosis in Canada are reimbursed by the Common Drug Review (CDR)-participating drug plans, including terbinafine and itraconazole, and there is no evidence to suggest that topical efinaconazole fulfills an unmet need in treating this condition. 2. There are no randomized controlled trials (RCTs) in which efinaconazole has been compared directly with other treatments used to treat onychomycosis in Canada, and the results of an indirect treatment comparison (ITC), while having limitations, suggested that topical efinaconazole was less effective than oral terbinafine 250 mg daily and itraconazole 200 mg daily at inducing mycologic cure of onychomycosis |
|---|---|
| Physical Description: | 1 PDF file (7 pages) |